Patrick Duxbury

Patrick Duxbury helps clients to research, develop, manufacture and sell pharmaceutical, biotech and medical device products, using his extensive experience of structuring and executing transactions in the life sciences sector.

Patrick was a microbiologist and geneticist before re-qualifying as a lawyer in 1993 with first class honours. He now specialises in all aspects of transactional work in the life sciences sector. He has helped clients including Argenx, AstraZeneca, Astellas, MedImmune, Astex Therapeutics, Crescendo Biologics, Epidarex, ERS Genomics, GlaxoSmithKline (GSK), Heptares Therapeutics, Kymab, Immunocore and SROne on significant M&A transactions, licensing and collaboration deals and fundraisings.

Thanks to his deep knowledge of the world in which he operates, Patrick delivers his clients a unique mix of regulatory, antitrust, IP, corporate and dispute resolution advice, helping many of the sector's key players.

Recent deals include advising AstraZeneca on a $6.9 billion cancer drug collaboration agreement with Daiichi Sankyo Company Limited, an $8.5bn oncology deal with Merck, on AstraZeneca's $300 million disposal of the rights to cancer drug Caprelsa to Genzyme and its $1.275bn collaboration with Innate Pharma. He has also recently advised Heptares Therapeutics Limited and Argenx BV, and Immunocore on several strategic license and collaboration transactions.

Patrick is a well known speaker on topics relating to transactions in the life sciences sector. He teaches on the BIO Advanced Business Development Course in both the US and Europe.


Patrick is ranked as the only 'Star Individual' for Life Sciences: Transactional in Chambers UK 2017 and is ranked as an IP Star in the 2017 edition of Managing Intellectual Poperty. Patrick has also been awarded the Lexology Client Choice Award 2016 and 2017 for Healthcare and Life Sciences in the UK. Patrick is also ranked in the Who's Who Thought Leader for Life Sciences publication and received the title 'Life Sciences - Transactional Lawyer of the Year 2019' at the prestigious, international, Who's Who Legal Awards 2019.

"Patrick Duxbury is one of the most respected transactional lawyers in the life sciences sector. He "combines a very sophisticated approach to contract construction and negotiation with sage advice that we have come to appreciate and trust greatly," said one interviewee." - Chambers UK 2015.

Patrick was recognised as a 'patent star' in the IP Stars guide 2017.

The Gowling WLG UK IP transaction team won the IP Transaction Team of the Year Award from MIP in 2018 and TMT team of the year at the British Legal Awards 2018 on the back of their work for AstraZeneca on its deal with Merck.


  • Working with Cambridge Antibody Technology Group (and now MedImmune) over the 15 years on numerous business-critical licence and collaboration deals including transactions with Amgen, Dyax, Micromet, Wyeth and Merck. Patrick acted for MedImmune on its widely publicised in-licence of the Phase III antibody, Tremelimumab, from Pfizer and its five antibody product deal with Amgen, which was one of the biggest deals of 2012.
  • Patrick has known Astex Therapeutics for many years and has helped the company through all of its significant transactions, including its widely publicised licence and collaboration deals with AstraZeneca, Novartis ( which has resulted in the cancer drug Kisqali), J&J and GSK and its merger with SuperGen.
  • He also advised Astellas on its Phase III product in-licence from Basilea Pharmaceuticals and was on hand to help the company through the restructuring of that deal in 2014.
  • Patrick has built up a strong relationship with GSK, and worked with it on the creation of Convergence Pharmaceuticals and Autifony Therapeutics (both funded by SV Life Sciences) and Nerre Therapeutics. He advised GSK on its 400 million Euro deal with MorphoSys.
  • Patrick has represented AstraZeneca on a large number of transactions including recent partnering deals with Sanofi, Pieris, Takeda and Eli Lilly. He also acted for AstraZeneca on the disposal of the rights to cancer drug Caprelsa to Genzyme and on its $8billion collaboration with Merck in the IO space. This transaction also won the Scrip licensing deal of the year for 2018.
  • Patrick has acted for Heptares Therapeutics for many years including on its transactions with Morphosys, Cubist and its $3.25 billion collaboration with Allergan.
  • Patrick has acted for Argenx on all of its significant partnering deals including with Leo, Abbvie and Shire.
  • Patrick advised Crescendo Biologics on its transaction with Takeda, a deal which won the Scrip licensing deal of the year for 2017.
  • Patrick also acts for a range of life science investors such as Epidarex and SROne.
  • Patrick recently advised Immunocore on its transaction with Genentech for a phase 1 ready asset.